A Network Pharmacology to Explore the Mechanism of Calculus Bovis in the Treatment of Ischemic Stroke

Fangchen Liu,1,2 Ling Li,3 Jian Chen,3 Ying Wu,1 Yongbing Cao,3 and Ping Zhong1,4

1Department of Neurology, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China
2Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
3Institute of Vascular Disease, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China
4Department of Neurology, Shidong Hospital of Yangpu District, Shanghai 200090, China

Background. Calculus Bovis is a valuable Chinese medicine, which is widely used in the clinical treatment of ischemic stroke. The present study is aimed at investigating its target and the mechanism involved in ischemic stroke treatment by network pharmacology.

Methods. Effective compounds of Calculus Bovis were collected using methods of network pharmacology and using the Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM) and the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). Potential compound targets were searched in the TCMSP and SwissTargetPrediction databases. Ischemic stroke-related disease targets were searched in the Drugbank, DisGeNet, OMIM, and TTD databases. These two types of targets were uploaded to the STRING database, and a network of their interaction (PPI) was built with its characteristics calculated, aiming to reveal a number of key targets. Hub genes were selected using a plug-in of the Cytoscape software, and Gene Ontology (GO) biological processes and pathway enrichment analyses of Kyoto Encyclopedia of Genes and Genomes (KEGG) were conducted using the clusterProfiler package of R language.

Results. Among 12 compounds, deoxycorticosterone, methyl cholate, and biliverdin were potentially effective components. A total of 344 Calculus Bovis compound targets and 590 ischemic stroke targets were found with 92 overlapping targets, including hub genes such as TP53, AKT, PIK2CA, MAPK3, MMP9, and MMP2. Biological functions of Calculus Bovis are associated with protein hydrolyzation, phosphorylation of serine/threonine residues of protein substrates, peptide bond hydrolyzation of peptides and proteins, hydrolyzation of intracellular second messengers, antioxidation and reduction, RNA transcription, and other biological processes.

Conclusion. Calculus Bovis may play a role in ischemic stroke by activating PI3K-AKT and MAPK signaling pathways, which are involved in regulating inflammatory response, cell apoptosis, and proliferation.

1. Introduction

Stroke is an acute cerebrovascular disease with typical clinical manifestations of sudden weakness in one side of the face, arms, or legs; sudden faintness; and unconsciousness. Ischemic stroke, the most common form of stroke, accounts for 70–80% of the total number of cases among stroke patients [1]. In China, deaths due to cerebrovascular diseases accounted for more than 20% of the total deaths in 2018 [2]. The rehabilitation of patients with ischemic stroke is often ineffective which brings a heavy burden to society and families. Currently, tissue-type plasminogen activator (tPA) is the only approved treatment for acute ischemic stroke [3–5]. However, its clinical application is greatly
limited due to the narrow treatment time window, high bleeding risk, and many contraindications [6]. In China, stroke has been managed with herbs or other Chinese methods for thousands of years. Chinese herbal medicine are now widely accepted as the main complementary treatment in East Asia, North America, and Europe because of their good therapeutic effect, low toxicity, and low cost [7–9].
### Table 1: Active ingredients of *Calculus Bovis*.

| Mol ID       | Mol name                                                                 | 2D structure | OB (%) | DL |
|--------------|---------------------------------------------------------------------------|--------------|--------|----|
| MOL000263    | Oleanolic acid                                                            |              | 29.02  | 0.76|
| MOL000298    | Ergosterol                                                                |              | 14.29  | 0.72|
| MOL000511    | Ursolic acid                                                              |              | 16.77  | 0.75|
| MOL008834    | Bilicerdin                                                                |              | 23.79  | 0.75|
| MOL008835    | 3-[2-[[3-(2-Carboxyethyl)-4-methyl-5-[(E)-(4-methyl-5-oxo-3-vinyl-2-pyrrolylidene)methyl]-1H-pyrrol-2-yl][methyl]-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-2-pyrrolylidene)methyl]-1H-pyrrol-3-yl]propanoic acid |              | 16.53  | 0.75|
| MOL008838    | Methyl (4R)-4-[(3R,5S,7S,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate |              | 32.32  | 0.76|
| MOL008839    | Methyl desoxycholate                                                      |              | 34.63  | 0.73|
| MOL008840    | 2-[(3alpha,12alpha-Dihydroxy-24-oxo-5beta-cholan-24-yl)amino]ethanesulfonic acid |              | 15.92  | 0.87|
| MOL008843    | Cherianoine                                                               |              | 27.32  | 0.12|
Calculus Bovis, one of the most commonly used Chinese herbs for stroke, has been used for over 2,000 years in China. It was first described in “Shen Nong Ben Cao Jing” as a medication with a bitter taste and cooling nature [10]. And it has been applied in conditions like loss of consciousness due to stroke, epilepsy, mania, and other mental disorders. It was shown that Calculus Bovis protects the brain through its anti-inflammatory, antiapoptosis [11], antilipid peroxidation [12], and antioxidative stress effects [13]. It is well known that herbs have multiple ingredients targeting multiple sites and multiple pathways [14, 15]. Currently, Calculus Bovis and its formulas are widely used to treat ischemic stroke, but the mechanisms underlying its therapeutic effects have not been studied intensively.

Network pharmacology for Chinese herbs is developed to decipher interactions between herbs and diseases at a system level by analysing the network between herbs, compounds, targets, diseases, and genes [16–19]. In the present study, our aim is to reveal the underlying mechanisms of Calculus Bovis in managing ischemic stroke by network pharmacology methods, which will lay the foundation for future pharmacological and clinical studies on ischemic stroke. The protocol of our experimental procedures is shown in Figure 1.

### 2. Materials and Methods

#### 2.1. Data Acquisition

##### 2.1.1. Prediction of Compounds of Calculus Bovis and Their Targets. Compounds of Calculus Bovis were collected from the herbal platform TCMSP and BATMAN-TCM. The TCMSP (https://tcmspw.com/tcmsp.php) is a systems pharmacology platform for herbs providing information about compounds and their targets [20]. The BATMAN-TCM (http://bionet.ncpsb.org/batman-tcm/) is an online bioinformatics analysis tool comprised of functions like target prediction for herbs and target analysis [21]. When “NIU HUANG (Calculus Bovis)” was typed in the “Cluster name,” “Score cutoff” value was set at 20, and “Adjusted p value” was set at 0.05, compounds of Calculus Bovis and their targets would be displayed. In addition, potential targets could be searched in the TCMSP and SwissTargetPrediction (http://www.swisstargetprediction.ch/) databases [22] to further confirm the targets of compounds derived from Calculus Bovis.

Names of target proteins were translated into gene names in the UniProt (http://www.uniprot.org/) database. If there was overlap in their target genes, the duplicates were deleted. Similarly, when the gene names of the protein targets were not found in the Uniprot database, they were deleted. SMILES IDs of compounds contained in Calculus Bovis were searched in the PubChem (https://pubchem.ncbi.nlm.nih.gov/) database, and their targets were predicted using SwissTargetPrediction after setting “Homo sapiens.” After collecting targets from the TCMSP, BATMAN-TCM, and SwissTargetPrediction databases, the duplicates were deleted.

##### 2.1.2. Prediction of Pharmacodynamics. In pharmacological studies, absorption, distribution, metabolism, and excretion (ADME) are key indices for identifying specific drugs [23]. Herein, 2 key parameters related to ADME, namely, oral bioavailability (OB) and drug-like activities (DL), were analyzed to explore potential bioactive compounds in Calculus Bovis. Based on the content of known compounds, OB and DL were set at ≥15% and ≥0.1, respectively. It has been reported that ergosterol (MOL000298; OB: 14.29%; DL: 0.72) is an indispensable compound of Calculus Bovis [24, 25] and was included in the present study. All compounds included in the present study were supported by the literature.

##### 2.1.3. Collection of Disease Targets of Ischemic Stroke. Key words such as “ischemic stroke,” “cerebral ischemic stroke,” and “brain ischemia” were used, and “Homo sapiens” was
their degrees of freedom increase.

**Table 2: Calculus Bovis compound-candidate target network parameters.**

| Network parameter         | Values       |
|---------------------------|--------------|
| Number of nodes           | 362          |
| Network density           | 0.011        |
| Network diameter          | 5            |
| Network heterogeneity     | 3.212        |
| Average number of neighbors | 3.901      |
| Characteristic path length | 3.236       |
| Shortest paths            | 130682 (100%)|
| Network centralization    | 0.304        |

**Figure 2:** Calculus Bovis compound-target network. Note: circles represent compounds, triangles represent targets, and their colors darken as their degrees of freedom increase.

**Figure 3:** Venn diagram of Calculus Bovis targets and ischemic stroke disease targets. CB: Calculus Bovis target; IS: ischemic stroke disease target.
selected for species. They were searched in the Drugbank [26], DisGeNet [27], OMIM [28], and TTD databases [29], and duplicate genes were deleted.

2.1.4. Venny Plotting. Both compound targets and disease targets were uploaded to the website of Venny 2.1.0 (https://bioinfogp.cnb.csic.es/tools/venny/); overlapping genes were the potential targets of bioactive compounds, and they interact with the body in ischemic stroke.

2.1.5. Protein-Protein Interaction (PPI). The STRING (https://string-db.org) database has collected a large number of well-known or predicted protein-protein interaction results [30]. Overlapping genes from Venny plots were uploaded to the database and “Homo sapiens” was selected for species, high confidence (0.700) was set for the minimum required interaction score, and irrelevant targets were concealed. As a result, a network map showing interactions between individual targets was rendered.

2.2. Network Construction and Hub Gene Selection. Network analysis facilitates interpretation of relationships between herbs, compounds, diseases, and genes. In the present study, two networks were constructed using Cytoscape 3.7.0 (https://cytoscape.org) [31]: (1) a network of Calculus Bovis compounds and compound targets and (2) a PPI network of Calculus Bovis compound targets and a PPI network of Calculus Bovis treating ischemic stroke targets after connecting Calculus Bovis compound targets and disease targets. Topographical analysis for networks was completed using the NetworkAnalyzer tool in Cytoscape. Overlapping genes, also named Hub genes, were selected from the PPI networks using the cytoHubba plug-in in Cytoscape and 3 algorithms were used in the calculations. The latter included degree of freedom, Maximum Neighborhood Component (MNC), and Maximal Clique Centrality (MCC).

2.3. Gene Functions and Pathway Enrichment Analysis. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted using the clusterProfiler package of R (R 4.0.2 for Windows) to identify biological processes and pathways with systemic involvement. Biological processes and pathways with a significant difference were selected, and their numbers of enrichment as well their as p values were ranked. The top 20 results from the GO enrichment and KEGG pathway enrichment analyses were presented. Visualization of these pathways with a p value < 0.05 was completed using the R software package.

3. Results and Analysis

A total of 12 bioactive compounds were found after ADME screening, and all of them have been verified in other studies.

3.1. Calculus Bovis Compound-Target Network. A total of 344 targets were found by 12 bioactive compounds of Calculus Bovis. Details of these ingredients are listed in Table 1, and the map of the compound-target network is shown in Figure 2. Circles represent compounds of Calculus Bovis, and triangles represent the targets; their colors are darkened as their degrees of freedom increased. There were 362 nodes and 706 edges with a network density of 0.011 and a network diameter of 5. Details of these parameters are listed in Table 2.

3.2. Disease Targets of Ischemic Stroke. Using key words listed in Section 2.1.3, 74 disease targets were found in the Drugbank database, 313 were found in the DisGeNet database.
Figure 5: Continued.
Figure 5: The PPI network of *Calculus Bovis* compound targets against ischemic stroke (IS): (a) the original PPI data generated from the STRING database showing detailed interactions of the targets; (b) the PPI network constructed using Cytoscape (version 3.7.0); (c) the top 15 genes were calculated from the PPI network by the degree of freedom, MNC, and MCC, and the overlapping genes were then screened by Venn diagrams; (d) the PPI network of hub genes.

Table 3: GO enrichment analysis results of *Calculus Bovis* targets.

| No. | ID       | Description                                                                 | Count | p value          |
|-----|----------|------------------------------------------------------------------------------|-------|------------------|
| 1   | GO:0005216 | Ion channel activity                                                         | 14    | 1.1591 × 10^{-10}|
| 2   | GO:0015267 | Channel activity                                                             | 14    | 3.57104 × 10^{-10}|
| 3   | GO:0022803 | Passive transmembrane transporter activity                                   | 14    | 3.67058 × 10^{-10}|
| 4   | GO:0022836 | Gated channel activity                                                       | 13    | 7.88226 × 10^{-11}|
| 5   | GO:0005261 | Cation channel activity                                                      | 11    | 1.25701 × 10^{-8}  |
| 6   | GO:0046873 | Metal ion transmembrane transporter activity                                 | 11    | 1.85161 × 10^{-7}  |
| 7   | GO:0030594 | Neurotransmitter receptor activity                                            | 9     | 1.68357 × 10^{-10}|
| 8   | GO:0015276 | Ligand-gated ion channel activity                                             | 8     | 1.76915 × 10^{-8}  |
| 9   | GO:0022834 | Ligand-gated channel activity                                                | 8     | 1.76915 × 10^{-8}  |
| 10  | GO:0098960 | Postsynaptic neurotransmitter receptor activity                              | 7     | 3.22861 × 10^{-9}  |
| 11  | GO:0005230 | Extracellular ligand-gated ion channel activity                               | 6     | 1.78299 × 10^{-7}  |
| 12  | GO:0099529 | Neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential | 5 | 6.54501 × 10^{-7} |
| 13  | GO:0022824 | Transmitter-gated ion channel activity                                       | 5     | 1.78703 × 10^{-6}  |
| 14  | GO:0022835 | Transmitter-gated channel activity                                           | 5     | 1.78703 × 10^{-6}  |
| 15  | GO:0016229 | Steroid dehydrogenase activity                                               | 4     | 5.40 × 10^{-6}      |
| 16  | GO:0016628 | Oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor | 4 | 1.58 × 10^{-6}     |
| 17  | GO:1904315 | Transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential | 4 | 1.78589 × 10^{-5} |
| 18  | GO:0022851 | GABA-gated chloride ion channel activity                                     | 3     | 9.83 × 10^{-6}      |
| 19  | GO:0042166 | Acetylcholine binding                                                        | 3     | 2.32 × 10^{-5}      |
| 20  | GO:0015271 | Outward rectifier potassium channel activity                                 | 3     | 1.56 × 10^{-5}      |
after screening for values above the average, 322 were found in the OMIM database, and 10 were found in the TTD database. A total of 590 targets were found after deleting gene duplicates.

3.3. Prediction of Calculus Bovis Targets in Ischemic Stroke.
After entering compound targets and disease targets to Venny 2.1.0 in the form of gene names, 92 overlapping genes were found (see Figure 3). These genes were the shared targets of the bioactive compounds and disease targets in ischemic stroke.

3.4. Construction of PPI Networks

3.4.1. The PPI Network of Calculus Bovis Targets. PPI networks have been widely used in studying protein-protein interactions in different diseases. To construct the PPI network of Calculus Bovis targets, 12 compounds were connected with 344 targets in the TCMSP and the SwissTargetPrediction databases, and they were imported into the STRING database (species: Homo sapiens; minimum required interaction score: high confidence (0.700)), and the PPI network was visualized after reconstructing it with Cytoscape (version 3.7.0). As shown in Figure 4, colors darkened as the degree of freedom increased. This PPI network contained 322 nodes and 2195 edges with a diameter of 8 and an average number of neighbors of 13.634. It showed that TP53 (degree = 82), AKT1 (degree = 67), MAPK1 (degree = 67), PIK3CA (degree = 63), SRC (degree = 58), MAPK3 (degree = 56), VEGFA (degree = 52), HSP90AA1 (degree = 48), JUN (degree = 46), EGFR (degree = 46), MAPK8 (degree = 45), TNF (degree = 40), and CASP3 (degree = 40) were the key nodes of this PPI network.

3.4.2. The PPI Network of Calculus Bovis-Ischemic Stroke Targets and Hub Genes. To explore the potential therapeutic mechanisms of Calculus Bovis in managing ischemic stroke, 92 shared targets by Calculus Bovis compounds and ischemic stroke were connected and imported into the STRING database as shown in Figure 5(a). The PPI network of Calculus Bovis-ischemic stroke targets were constructed by visualizing the results using Cytoscape (Figure 5(b)). This PPI network had 83 nodes and 403 edges with a network diameter of 6 and an average number of neighbors of 9.711. The top 10 targets with the highest degree of freedom were TP53 (degree = 82), AKT1 (degree = 67), MAPK1 (degree = 67), PIK3CA (degree = 63), SRC (degree = 58), MAPK3 (degree = 56), VEGFA (degree = 52), HSP90AA1 (degree = 48), JUN (degree = 46), EGFR (degree = 46), MAPK8 (degree = 45), TNF (degree = 40), and CASP3 (degree = 40) were the key nodes of this PPI network.

Figure 6: Bubble plot of GO enrichment analysis of Calculus Bovis targets. Bubble plot: letters on the left are GO names, numbers on the bottom are the proportions of genes, sizes of the circles indicate the numbers of enriched genes, and colors reflect p values. The redder the colors are, the more enriched the genes are, and the smaller the p values are.
PTGS2 (degree = 22), and IL-1B (degree = 20). A total of 6 Hub genes were found using 3 algorithms: degree of freedom, Maximum Neighborhood Component (MNC), and Maximal Clique Centrality (MCC) (Figure 5(c)). These genes were TP53, AKT1, PIK3CA, MAPK3, MMP9, and MMP2. Their network of interactions is shown in Figure 5(d). In addition, TP53, AKT1, MAPK1, VEGFA, PIK3CA, and MAPK3 were among the top 10 candidates ranked by degree of freedom.

3.5. GO Enrichment Analysis. To further investigate the underlying mechanism of Calculus Bovis in managing ischemic stroke, 344 targets and 92 shared targets were collected for GO enrichment analysis.

3.5.1. GO Enrichment Analysis for Calculus Bovis Targets. Twenty results were selected based on their p values and their numbers of enrichment. They were primarily involved in ion channel activity (GO:0005216), channel activity (GO:0015267), passive transmembrane transporter activity (GO:0022803), gated channel activity (GO:0022836), cation channel activity (GO:0005261), metal ion transmembrane transporter activity (GO:0046873), neurotransmitter receptor activity (GO:0030594), ligand-gated ion channel activity (GO:0015276), ligand-gated channel activity (GO:0022834), postsynaptic neurotransmitter receptor activity (GO:0098960), extracellular ligand-gated ion channel activity (GO:0005230), neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential (GO:0099529), transmitter-gated ion channel activity (GO:0022824), transmitter-gated channel activity (GO:0022835), and steroid dehydrogenase activity (GO:0016229). Details are listed in Table 3. Results are presented using a bubble plot and a column chart using the R package.

(1) Bubble Plot. In the bubble plot, letters on the left are GO names, numbers on the bottom are the proportions of genes, sizes of circles indicate the numbers of enriched genes, and colors reflect p values. The redder the colors are, the more enriched the genes are, and the smaller the p values are (Figure 6).

(2) Column Chart. In the column chart, letters on the left are GO names, numbers on the bottom are the numbers of genes enriched on GO, and p reflects significance of enrichment. The redder the colors are, the more enriched the genes are, and the smaller the p values are (Figure 7).

3.5.2. GO Enrichment Analysis of Shared Targets of Calculus Bovis and Ischemic Stroke. GO enrichment analysis was performed against the 92 shared targets. The top 20 were selected based on their p values and numbers of enrichment, including endopeptidase activity (GO:0004175); protein serine/threonine kinase activity (GO:004674);
metallopeptidase activity (GO:0008237); phosphoric diester hydrolase activity (GO:0008081); heme binding (GO:0020037); tetrapyrrole binding (GO:0046906); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); serine-type peptidase activity (GO:0008237); phosphoric diester hydrolase activity (GO:0008081); heme binding (GO:0020037); tetrapyrrole binding (GO:0046906); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); serine-type peptidase activity (GO:0008237). Results were visualized as a bubble plot (Figure 8) and a column chart (Figure 9) using the R package.

**Table 4**: GO enrichment analysis results of shared targets by *Calculus Bovis* and ischemic stroke.

| No. | ID          | Description                                                                 | Count | p value        |
|-----|-------------|------------------------------------------------------------------------------|-------|----------------|
| 1   | GO:0004175  | Endopeptidase activity                                                       | 15    | 5.14505 × 10⁻⁸ |
| 2   | GO:0004674  | Protein serine/threonine kinase activity                                     | 12    | 2.81896 × 10⁻⁶ |
| 3   | GO:0008237  | Metallopeptidase activity                                                    | 9     | 4.20451 × 10⁻⁷ |
| 4   | GO:0008081  | Phosphoric diester hydrolase activity                                        | 8     | 3.02315 × 10⁻⁸ |
| 5   | GO:0020037  | Heme binding                                                                 | 8     | 5.05803 × 10⁻⁷ |
| 6   | GO:0046906  | Tetrapyrrole binding                                                         | 8     | 8.71647 × 10⁻⁷ |
| 7   | GO:0016705  | Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | 8     | 1.74788 × 10⁻⁶ |
| 8   | GO:0008236  | Serine-type peptidase activity                                               | 8     | 4.78249 × 10⁻⁶ |
| 9   | GO:0017171  | Serine hydrolase activity                                                    | 8     | 5.61466 × 10⁻⁶ |
| 10  | GO:0031406  | Carboxylic acid binding                                                      | 8     | 7.36664 × 10⁻⁶ |
| 11  | GO:0043177  | Organic acid binding                                                         | 8     | 1.14448 × 10⁻⁵ |
| 12  | GO:0004222  | Metalloendopeptidase activity                                                | 7     | 1.07557 × 10⁻⁶ |
| 13  | GO:0001085  | RNA polymerase II transcription factor binding                               | 7     | 1.62174 × 10⁻⁵ |
| 14  | GO:0033293  | Monocarboxylic acid binding                                                  | 6     | 9.84665 × 10⁻⁷ |
| 15  | GO:0005504  | Fatty acid binding                                                           | 5     | 8.40369 × 10⁻⁷ |
| 16  | GO:0043560  | Insulin receptor substrate binding                                           | 4     | 2.19487 × 10⁻⁷ |
| 17  | GO:0036041  | Long-chain fatty acid binding                                                | 4     | 6.57868 × 10⁻⁷ |
| 18  | GO:0004114  | 3′,5′-Cyclic-nucleotide phosphodiesterase activity                           | 4     | 1.27273 × 10⁻⁵ |
| 19  | GO:0004112  | Cyclic-nucleotide phosphodiesterase activity                                | 4     | 1.47051 × 10⁻⁵ |
| 20  | GO:0016303  | 1-Phosphatidylinositol-3-kinase activity                                     | 3     | 1.58908 × 10⁻⁵ |

3.6. **KEGG Pathway Enrichment Analysis.** KEGG pathway enrichment analysis was performed for 344 *Calculus Bovis* targets and 92 shared targets.

3.6.1. **KEGG Pathway Enrichment Analysis for Calculus Bovis Targets.** Eighteen results were selected based on their p values and their numbers of enrichment. They were mainly involved in neuroactive ligand-receptor interaction (hsa04080), Alzheimer disease (hsa05010), calcium signaling pathway (hsa04020), nicotine addiction (hsa05033), steroid hormone biosynthesis (hsa00140), GABAergic synapse (hsa04727), morphine addiction (hsa05032), cholinergic synapse (hsa04725), retrograde endocannabinoid signaling (hsa04723), and cellular senescence (hsa04218) (see Table 5).

(1) **Bubble Plot.** In the bubble plot, letters on the left are KEGG names, numbers on the bottom are the proportions of genes, sizes of circles indicate the numbers of enriched genes, and colors reflect p values. The redder the colors are, the more enriched the genes are, and the smaller the p values are (Figure 10).

(2) **Column Chart.** In the column chart, letters on the left are KEGG names, numbers on the bottom are the numbers of genes enriched on KEGG, columns represent genes enriched on KEGG, and p reflects significance of enrichment. The redder the colors are, the more enriched the genes are, and the smaller the p values are (Figure 11).

3.6.2. **KEGG Pathway Enrichment Analysis for Shared Targets.** KEGG pathway enrichment analysis was performed on 92 shared targets, and 145 pathways were found. The top 20 candidates were selected based on their p values and numbers of enrichment, and they were involved in the PI3K–AKT signaling pathway (hsa04151), human papillomavirus infection (hsa05165), Kaposi sarcoma-associated herpesvirus infection (hsa05167), human cytomegalovirus infection (hsa05163), microRNAs in cancer (hsa05206), fluid shear stress and atherosclerosis (hsa05418), proteoglycans in
cancer (hsa05205), AGE-RAGE signaling pathway in diabetic complications (hsa04933), CAMP signaling pathway (hsa04024), prostate cancer (hsa05215), TNF signaling pathway (hsa04668), platelet activation (hsa04611), EGFR tyrosine kinase inhibitor resistance (hsa01521), small cell lung cancer (hsa05222), and endocrine resistance (hsa01522) (Table 6). Results were visualized as a bubble plot (Figure 12) and a column chart (Figure 13) using the R package.

4. Discussion

Network pharmacology was used in this study to investigate Calculus Bovis itself and its potential mechanism for the treatment of ischemic stroke through compound target network construction, PPI network analysis, GO enrichment analysis, and KEGG pathway analysis.

Network analysis of compound targets showed that deoxycorticosterone (MOL008846), methyl cholate (MOL008838), and biliverdin (MOL008834) had the most connections with these targets, suggesting that these 3 compounds might be the key compounds of Calculus Bovis.

Deoxycorticosterone is a type of steroid hormone possessing activities of the mineralocorticoid and serves as the precursor of aldosterone. It is involved in water and salt metabolism, playing an important role in electrolyte balance and in the volume of body fluid [32]. It has been reported that deoxycorticosterone and its derivatives—neurosteroids transformed in the fetal brain—protect the central nervous system. Inhibiting the production of neurosteroids increases basal cell death [33]. Neuroactive steroid hormones are involved in the regulation of diverse physiological functions, such as cell differentiation, neuroprotection, memory reinforcement, and amelioration of anxiety and pressure [34]. Methyl cholate is the methyl ester form of cholic acid, inhibiting the synthesis of cholesterol [35]. It has been reported that methyl cholate suppresses the growth of certain Gram-positive and Gram-negative bacteria [36] and has a good anti-inflammatory effect [37]. Biliverdin is a type of bile pigment, an oxidized product of heme. Emerging evidence has shown that biliverdin is an endogenous antioxidant facilitating the restoration of the tissue oxidation-reduction environment [38]. In the middle cerebral artery occlusion (MCAO) model, it significantly decreased the infarct area and the production of peroxides in the cortex [39]. These indicate that biliverdin plays a pivotal role in mitigating ischemic brain injury through its antioxidative stress effect. In addition, a single target was regulated by multiple compounds as shown in our network. Protein-tyrosine phosphatase 1B (PTPN1) was subject to the regulation of deoxycorticosterone,
Figure 9: Column chart of GO enrichment analysis of shared targets by *Calculus Bovis* and ischemic stroke.

Table 5: KEGG pathway enrichment analysis results of *Calculus Bovis* targets.

| No. | ID     | Description                                | Count | p value        |
|-----|--------|--------------------------------------------|-------|---------------|
| 1   | hsa04080 | Neuroactive ligand-receptor interaction    | 14    | 1.03 × 10⁻⁸   |
| 2   | hsa05010 | Alzheimer disease                          | 9     | 4.14 × 10⁻⁶   |
| 3   | hsa04020 | Calcium signaling pathway                  | 6     | 3.4 × 10⁻⁵    |
| 4   | hsa05033 | Nicotine addiction                         | 5     | 2.08104 × 10⁻⁴|
| 5   | hsa00140 | Steroid hormone biosynthesis               | 5     | 2.31001 × 10⁻⁴|
| 6   | hsa04727 | GABAergic synapse                          | 5     | 3.04528 × 10⁻⁴|
| 7   | hsa05032 | Morphine addiction                         | 5     | 3.73161 × 10⁻⁴|
| 8   | hsa04725 | Cholinergic synapse                         | 5     | 6.29559 × 10⁻⁴|
| 9   | hsa04723 | Retrograde endocannabinoid signaling       | 5     | 1.033601 × 10⁻³|
| 10  | hsa04218 | Cellular senescence                        | 5     | 1.40748 × 10⁻³|
| 11  | hsa04330 | Notch signaling pathway                    | 4     | 1.594499 × 10⁻³|
| 12  | hsa04115 | p53 signaling pathway                      | 4     | 2.068787 × 10⁻³|
| 13  | hsa05204 | Chemical carcinogenesis                    | 4     | 2.107734 × 10⁻³|
| 14  | hsa04540 | Gap junction                               | 4     | 2.532292 × 10⁻³|
| 15  | hsa04970 | Salivary secretion                         | 4     | 2.652055 × 10⁻³|
| 16  | hsa04914 | Progesterone-mediated oocyte maturation    | 4     | 3.294802 × 10⁻³|
| 17  | hsa05030 | Cocaine addiction                          | 3     | 3.367718 × 10⁻³|
| 18  | hsa04340 | Hedgehog signaling pathway                 | 3     | 3.567181 × 10⁻³|
oleanolic acid, ergosterol, ursolic acid, biliverdin, bilirubin, methyl cholate, methyl deoxycholate, taurodeoxycholic acid, and others. PTPs are involved in regulating differentiation and survival of neurons and have also been reported to be a new target of antiplatelet therapy [40]. PTPN1 is a negative regulator of the leptin and insulin signaling pathways, and PTP1B knockout mice are exempt from obesity and diabetes, both of which are risk factors of ischemic stroke [41]. Similarly, other targets like 11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1), dual-specificity phosphatase Cdc25A (CDC25A), cytochrome P450 19A1 (CYP19A1), progesterone receptor (PGR), and androgen receptor (AR) were also regulated by two or more compounds. The present study revealed not only relationships between *Calculus Bovis* compounds and their targets but also the potential pharmacological effects of *Calculus Bovis*, which reflects the multi-compound and multitarget theory of modern drugs.

Furthermore, the PPI network demonstrated information not only about protein homology and coexpression but also about protein-protein interactions. Our PPI analysis showed that *Calculus Bovis* influences ischemic stroke through its impact on a complex biological network, including TP53, AKT1, MAPK1, VEGFA, TNF, PIK3CA, MAPK3, MMP9, PTGS2, and IL1B. Hub gene screening revealed that TP53, AKT1, PIK3CA, MAPK3, MMP9, and MMP2 were essential in this process. The above potential targets for the action of *Calculus Bovis* in the treatment of ischemic stroke are our first discoveries.

TP53, cellular tumor antigen p53, is a tumor suppressing gene. It promotes cell apoptosis, increases gene stability, and suppresses tumorigenesis [42]. It has been reported that methylation of the TP53 promoter was increased in ischemic stroke, and this increase was associated with the thickness of the intima of the carotid artery, degree of atherosclerosis of the carotid artery, and levels of homocysteine in the peripheral blood [43]. More evidence showed that TP53 induced glycolysis, and apoptosis regulator (TIGAR) suppressed glycolysis, increased pentose-phosphate pathway flux, and maintained the function of mitochondria. As a result, it protected the brain from ischemic injury [44]. The Tp53 Arg/Arg genotype has been considered a genetic marker for predicting poor prognosis after ischemic stroke [45]. AKT1 (serine/threonine-protein kinase AKT) codes for the serine/threonine-protein kinase which regulates apoptosis proteins.

![Image](image-url)
and transcription factors. It is the key player in regulating cell survival, growth, apoptosis, and proliferation in the presence of growth factors and external stimuli, especially brain ischemia and reperfusion injury. AKT1 gene variance is closely related to metabolic syndrome, a risk factor of stroke [46]. AKT/PKB was involved in brain ischemia, and its activity was related to the extent of ischemic injury. Activation of AKT was the key factor in determining survival of neurons after ischemic injury [47]. PIK3CA codes for the p110 subunit of the phosphatidylinositol 3-kinases (PI3Ks), and its mutations decrease cell apoptosis and increase the activity of downstream PI3Ks. It is known that activation of PI3K/AKT promotes repair of neural injury due to ischemic stroke [48, 49] and angiogenesis in the hypoxic environment in vitro [50]. Consequently, it protects the rat brain from inflammation resulting from ischemia-reperfusion injury [51]. Activation of the TrkB/PI3K/AKT pathway also increases activation of Nrf2 and its translocation to the nucleus, which plays a pivotal role in protecting the central nervous system from oxidative stress [52].

MAPK (mitogen-activated protein kinase) is involved in reaction to physiological and pathological stimuli, such as cytokines, neurotransmitters, hypoxia, and hypoglycemia [53]. MAPK3 (MAP kinase ERK1) and MAPK1 (MAP kinase ERK2) form ERK1/2, a subfamily of MAPK. They play important roles in cell proliferation, differentiation, migration, invasion, apoptosis, and other biological processes. In the H$_2$O$_2$ induced PC12 cell injury model, activation of the AKT and ERK1/2 pathways leads to an antioxidation effect [54]. Levels of ERK1 and ERK2 were increased after ischemic stroke onset. In vitro research further revealed that activation of ERK1/2 increased neuronal apoptosis, indicating that they are important targets for ischemic stroke treatment [55].

GO and KEGG pathway enrichment analyses for Calculus Bovis targets showed that Calculus Bovis was closely related to ion channel activity, neurotransmitter receptor activity, and other physiological functions. Pathway enrichment analysis demonstrated its involvement in a number of pathways in the central nervous system, calcium-related signaling, and so on. These were consistent with the analgesic and antiepilepsy effects of Calculus Bovis and its clinical application in these fields, which lays the theoretical foundation for managing ischemic stroke using Calculus Bovis.

GO enrichment and KEGG pathway analyses against the shared 92 targets showed that Calculus Bovis was closely related to hydrolyzation of proteins, phosphorylation of serine/threonine residues of protein substrates, peptide bond hydrolyzation of peptides and proteins, hydrolyzation of second intracellular messengers, antioxidation and reduction, RNA transcription, and other biological processes. Among them, 15 (16.3%) were related to endopeptidase activities of the matrix metalloproteinase (MMPs) family (MMP1, MMP2, MMP3, MMP8, MMP9, MMP10, and MMP12) and the cysteine-containing aspartate-specific peptidase

Figure 11: Column chart of KEGG pathway enrichment analysis of Calculus Bovis targets. Column chart: letters on the left are KEGG names, numbers on the bottom are the numbers of genes enriched on KEGG, columns represent genes enriched on KEGG, and $p$ reflects the significance of enrichment. The redder the colors are, the more enriched the genes are, and the smaller the $p$ values are.
family (CASP1, CASP2, and CASP3). MMPs are a type of highly conserved protease in nature, belonging to the family of zinc-dependent endopeptidases. They are capable of degrading extracellular matrix, growth factors, cytokines, and cell adhesion molecules. They are indispensable in inflammatory and immune reactions, angiogenesis, immune responses, inflammation, cell migration, proliferation, cell apoptosis, and other physiological and pathological processes [56]. Their mRNAs were dramatically increased in the cortex of the mouse ischemia model in which thrombus was induced [57]. Decreasing levels of MMPs significantly ameliorated transgression of neutrophils, which resulted in neuroprotection against ischemic stroke [58]. Targeted inhibition of the PI3K/AKT/MMP-9 signaling pathway suppressed tumor invasion and metastasis [59], but this has not been tested in neuronal cells. Caspases are closely related to apoptosis of eukaryocytes and regulation of cell proliferation as well as differentiation. Caspase 3 is the most important and indispensable one in the cascade of cell apoptosis. In brain ischemia, levels of CASP3 mRNA and protein were increased, and its activity was significantly reversed by a CASP3 inhibitor, preventing the hydrolyzation of poly(ADP-ribose) polymerase. Consequently, apoptosis was suppressed and neurological functions improved [60]. Neuroinflammation is a key pathological process, in which CASP1-activated inflamasomes play an essential role. It has been reported that CASP1 was increased in the mouse brain after cerebral ischemia, which was suppressed by a CASP1 inhibitor through decreasing the activation of microglial cells, protecting the brain from ischemic injury. These indicate that CASP1 is a potential drug target for ischemic stroke management [61]. Both in vitro and in vivo experiments have shown that activation of the PI3K/AKT pathway increases the phosphorylation of Bad and decreases the level of caspase-3, through which apoptosis is suppressed [62].

Another 12 genes (13.0%) are related to activities of protein serine/threonine kinases, consistent with the findings of the PI3K-AKT signaling pathway (24 enriched genes, 27.2%) in the KEGG pathway analysis. AKT is also named serine/threonine kinase, consistent with the findings of the PI3K-AKT signaling pathway (24 enriched genes, 27.2%) in the KEGG pathway analysis. AKT is also named serine/threonine kinase, whose activation is key for neuronal survival [63]. It is known that phosphorylated AKT was decreased in the infarct area after ischemia-reperfusion injury and increased in the penumbra after reperfusion. An inhibitor of PI3K decreased the level of phosphorylated AKT and increased the infarct area, indicating that PI3K/AKT is involved in the pathogenesis of brain ischemia and activation of AKT increases neuronal survival [64]. Among them, MAPK3 (ERK1) is not only a Hub gene involved in regulating the activity of protein serine/threonine kinases as shown by GO analysis but is also enriched in the PI3K-AKT signaling pathway. These suggest that MAPK3 is an important component of this network. Therefore, *Calculus Bovis* might protect the brain from ischemic stroke through its anti-inflammatory and antiapoptosis effects which are accomplished by interacting with the abovementioned key genes and pathways.

| No. | ID      | Description                                      | Count | p value       |
|-----|---------|--------------------------------------------------|-------|---------------|
| 1   | hsa04151| PI3K-AKT signaling pathway                       | 24    | 2.12708 × 10⁻¹³|
| 2   | hsa05165| Human papillomavirus infection                   | 20    | 2.45479 × 10⁻¹⁰|
| 3   | hsa05167| Kaposi sarcoma-associated herpesvirus infection  | 19    | 1.3448 × 10⁻¹³|
| 4   | hsa05163| Human cytomegalovirus infection                  | 18    | 2.23341 × 10⁻¹¹|
| 5   | hsa05206| MicroRNAs in cancer                              | 18    | 4.23388 × 10⁻⁹ |
| 6   | hsa05418| Fluid shear stress and atherosclerosis           | 17    | 8.25476 × 10⁻¹⁴|
| 7   | hsa05205| Proteoglycans in cancer                          | 17    | 4.88669 × 10⁻¹¹|
| 8   | hsa04933| AGE-RAGE signaling pathway in diabetic complications| 16   | 6.21323 × 10⁻¹⁵|
| 9   | hsa04024| cAMP signaling pathway                           | 16    | 1.04013 × 10⁻⁹ |
| 10  | hsa05215| Prostate cancer                                  | 14    | 1.54571 × 10⁻¹²|
| 11  | hsa04668| TNF signaling pathway                            | 14    | 1.16611 × 10⁻¹¹|
| 12  | hsa04611| Platelet activation                              | 13    | 6.34665 × 10⁻¹⁰|
| 13  | hsa01521| EGFR tyrosine kinase inhibitor resistance         | 12    | 3.67514 × 10⁻¹¹|
| 14  | hsa05222| Small cell lung cancer                           | 12    | 2.32309 × 10⁻¹⁰|
| 15  | hsa01522| Endocrine resistance                             | 12    | 4.93414 × 10⁻¹⁰|
| 16  | hsa04919| Thyroid hormone signaling pathway                | 12    | 5.80768 × 10⁻⁹ |
| 17  | hsa05212| Pancreatic cancer                                | 11    | 4.36655 × 10⁻¹⁰|
| 18  | hsa05210| Colorectal cancer                                | 11    | 1.70773 × 10⁻⁹ |
| 19  | hsa04657| IL-17 signaling pathway                          | 11    | 4.49095 × 10⁻⁹ |
| 20  | hsa05220| Chronic myeloid leukemia                         | 10    | 7.44115 × 10⁻⁹ |
Figure 12: Bubble plot of KEGG pathway enrichment analysis of shared targets.

Figure 13: Column chart of KEGG pathway enrichment analysis of shared targets.
5. Conclusion

Bioactive compounds, potential targets, and underlying mechanisms of *Calculus Bovis* were examined using network pharmacology methods. KEGG pathway analysis showed that the PI3K/AKT and the MAPK signaling pathways were the key targets for ischemic stroke treatment. The effect of *Calculus Bovis* was achieved through directly or indirectly regulating the above targets and pathways. Our results confirmed that *Calculus Bovis* was a multicomponent and multitarget drug with a multisystem character in the treatment of ischemic stroke, which laid the theoretical foundation for the development of drugs and therapeutic methods based on the results of *Calculus Bovis* in the future.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there is no conflict of interests.

Acknowledgments

The present study was supported by the Shanghai Municipal Committee of Science and Technology (through grant no. 19401935700 to Ping Zhong), the National Science and Technology Major Projects for “Major New Drugs Innovation and Development” (through grant no. 2018ZX09201008-002-092), and the Three-Year Action Plan of “Strong and Excellent Chinese Medicine” in Hongkou District (through grant no. HGY-MGB-2018-01-07 to Yongbing Cao).

Supplementary Materials

Supplementary 1. Table S1: all ingredients of *Calculus Bovis*. Supplementary 2. Table S2: targets of active ingredients of *Calculus Bovis*. (Supplementary Materials)

References

[1] S. I. Hay, A. A. Abajobir, K. H. Abate et al., “Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016,” *Lancet*, vol. 390, no. 10100, pp. 1260–1344, 2017.

[2] L. D. Wang, J. H. Wang, B. Peng, and Y. M. Xu, “Brief report on stroke prevention and treatment in China, 2019,” *Chinese Journal of Cerebrovascular Diseases*, vol. 17, no. 5, pp. 272–281, 2020.

[3] D. Keizman, P. Huang, M. A. Eisenberger et al., “Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination,” *European Journal of Cancer*, vol. 47, no. 13, pp. 1955–1961, 2011.

[4] A. P. Jadhav and T. G. Jovin, “Endovascular therapy for acute ischemic stroke: the standard of care,” *Brain circulation*, vol. 2, no. 4, pp. 178–182, 2016.

[5] S. Yoshimura, N. Sakai, K. Uchida et al., “Endovascular therapy in ischemic stroke with acute large-vessel occlusion: Recovery by Endovascular Salvage for Cerebral Ultra-Acute Embolism Japan Registry 2,” *Journal of the American Heart Association*, vol. 7, no. 9, 2018.

[6] J. F. Meschia, C. Bushnell, B. Boden-Alba et al., “Guidelines for the primary prevention of stroke,” *Stroke*, vol. 45, no. 12, pp. 3754–3832, 2014.

[7] T.-T. Sham, C.-O. Chan, Y.-H. Wang, J.-M. Yang, D. K.-W. Mok, and S.-W. Chan, “A review on the traditional Chinese medicinal herbs and formulae with hypolipidemic effect,” *BioMed Research International*, vol. 2014, Article ID 925302, 21 pages, 2014.

[8] L. J. Xiao and R. Tao, “Traditional Chinese medicine (TCM) therapy,” *Advances in Experimental Medicine and Biology*, vol. 1010, pp. 261–280, 2017.

[9] W. Xu, A. D. Towers, P. Li, and C. JP, “Traditional Chinese medicine in cancer care: perspectives and experiences of patients and professionals in China,” *European Journal of Cancer care*, vol. 15, no. 4, pp. 397–403, 2006.

[10] W. J. Kong, X. Y. Xing, X. H. Xiao, J. B. Wang, Y. L. Zhao, and M. H. Yang, “Multi-component analysis of bile acids in natural *Calculus bovis* and its substitutes by ultrasound-assisted solid-liquid extraction and UPLC-ELSD,” *Analyst*, vol. 137, no. 24, pp. 5845–5853, 2012.

[11] X. L. Xu, “Comparative Study on the Effects of Effective Components of Bezoar on Anti-Cerebral Infarction and Regulating Endoplasmic Reticulum Stress,” *Beijing University Of Chinese Medicine Medicine*, 2016.

[12] C. Y. Li, P. T. Li, Y. S. Pan, X. Jia, and K. L. Li, “Effects of compatibility of bezoar and gardenia on lipid peroxidation injury at different time of focal cerebral ischemia and reperfusion in rats,” *China Journal of Traditional Chinese Medicine and Pharmacy*, vol. 9, pp. 528–530, 2004.

[13] D. Shifen, L. Liming, Z. Shuoeng, and S. Jianning, “Protective effect of An-Gong-Niu-Huang-Wan (containing natural or artificial Moschus) on experimental cerebral ischemia in rats,” *Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology*, vol. 15, no. 1, pp. 85–90, 2013.

[14] X. Liu, J. Wu, D. Zhang, K. Wang, X. Duan, and X. Zhang, “A network pharmacology approach to uncover the multiple mechanisms of *Hedyotis diffusa* Wild. on colorectal cancer,” *Evidence-based Complementary and Alternative Medicine*, vol. 2018, Article ID 6517034, 12 pages, 2018.

[15] L. Gao, J. Hao, Y. Y. Niu et al., “Network pharmacology dissection of multiscale mechanisms of herbal medicines in stage IV gastric adenocarcinoma treatment,” *Medicine (Baltimore)*, vol. 95, no. 35, article e4389, 2016.

[16] S. Li, B. Zhang, D. Jiang, Y. Wei, and N. Zhang, “Herb network construction and co-module analysis for uncovering the...
combination rule of traditional Chinese herbal formulae," BioMed Informatics, vol. 11, Suppl 11, p. S6, 2010.

[17] M. Wang, Y. Qi, and Y. Sun, “Exploring the antitumor mechanisms of Zingiberis Rhizoma combined with Coptidis Rhizoma using a network pharmacology approach,” BioMed Research International, vol. 2020, Article ID 8887982, 18 pages, 2020.

[18] L. Wang, Y. Zhi, Y. Ye et al., “Identify molecular mechanisms of Jiangzhi decoction on nonalcoholic fatty liver disease by network pharmacology analysis and experimental validation,” BioMed Research International, vol. 2020, Article ID 8829346, 16 pages, 2020.

[19] L. Yang, H. Li, M. Yang et al., “Exploration in the mechanism of kaempferol for the treatment of gastric cancer based on network pharmacology,” BioMed Research International, vol. 2020, Article ID 5891016, 11 pages, 2020.

[20] J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, no. 1, p. 13, 2014.

[21] Z. Liu, F. Guo, Y. Wang et al., “BATMAN-TMC: a bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine,” Scientific Reports, vol. 6, no. 1, p. 21146, 2016.

[22] A. Daina, O. Michielin, and V. Zoete, “SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules,” Nucleic Acids Research, vol. 47, no. W1, pp. W357–W364, 2019.

[23] H. A. Barton, T. P. Pastoor, K. Baetcke et al., “The acquisition and application of absorption, distribution, metabolism, and excretion (ADME) data in agricultural chemical safety assessments,” Critical Reviews in Toxicology, vol. 36, no. 1, pp. 9–35, 2008.

[24] J. Jia, J. M. Sun, H. Zang, and H. Zhang, “Research progress on the chemical constituents and pharmacological activities of natural bezoar,” Journal of Chinese Medicine, vol. 33, no. 3, pp. 271–274, 2013.

[25] Z. L. Huang, “Pharmacological research and clinical application of bezoar and some of its components,” Chinese Traditional Patent Medicine, vol. 10, pp. 26–28, 1995.

[26] D. S. Wishart, Y. D. Feunang, A. C. Guo et al., “DrugBank 5.0: a major update to the DrugBank database for 2018,” Nucleic Acids Research, vol. 46, no. D1, pp. D1074–D1082, 2018.

[27] J. Piñero, N. Queralt-Rosinach, A. Bravo et al., “DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes,” Database: The Journal of Biological Databases and Curation, vol. 2015, 2015.

[28] A. Hamosh, A. F. Scott, J. S. Amberger, C. A. Bocchini, and V. McKusick, “Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders,” Nucleic Acids Research, vol. 33, no. Database issue, pp. D514–D517, 2005.

[29] Y. Wang, S. Zhang, P. Li et al., “Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics,” Nucleic Acids Research, vol. 48, no. D1, pp. D1031–D1041, 2020.

[30] D. Szklarczyk, A. L. Gable, D. Lyon et al., “STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets,” Nucleic Acids Research, vol. 47, no. D1, pp. D607–D613, 2019.

[31] P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003.

[32] C. A. Shaughnessy, A. Barany, and S. D. McCormick, “11-Deoxycortisol controls hydromineral balance in the most basal osmoregulating vertebrate, sea lamprey (Petromyzon marinus),” Scientific Reports, vol. 10, no. 1, p. 12148, 2020.

[33] J. J. Hirst, H. K. Palliser, D. M. Yates, T. Yawn, and D. W. Walker, “Neurosteroids in the fetus and neonate: potential protective role in compromised pregnancies,” Neurochemistry International, vol. 52, no. 4–5, pp. 602–610, 2008.

[34] A. M. Traisch, “5α-Reductases in human physiology: an unfolding story,” Endocrine Practice, vol. 18, no. 6, pp. 965–975, 2012.

[35] H. J. Kim, S. H. Yim, and I. S. Lee, “A cholesterol biosynthesis inhibitor from Rhizopus oryzae,” Archives of Pharmacal Research, vol. 27, no. 6, pp. 624–627, 2004.

[36] T. Sugai, M. Takizawa, M. Bakke, Y. Ohtsuka, and H. Ohta, “Efficient lipase-catalyzed preparation of long-chain fatty acid esters of bile acids: biological activity and synthetic application of the products,” Bioscience, Biotechnology, and Biochemistry, vol. 60, no. 12, pp. 2059–2063, 2014.

[37] Y. J. Tan, “Study on preparation of cholic acid-baicalin nasal liposome and its protective effect on cerebral ischemia reperfusion injury in rats,” Chengdu University of Traditional Chinese Medicine, 2019.

[38] H. M. Schipper, W. Song, A. Tavitiian, and M. Cressatti, “The sinister face of heme oxygeenase-1 in brain aging and disease,” Progress in Neurobiology, vol. 172, pp. 40–70, 2019.

[39] T. Yamashita, K. Deguchi, S. Nagotani, T. Kamiya, and K. Abe, “Gene and stem cell therapy in ischemic stroke,” Cell Transplantation, vol. 18, no. 9, pp. 999–1002, 2009.

[40] L. Tautz, Y. A. Senis, C. Oury, and S. Rahmouni, “Perspective: tyrosine phosphatases as novel targets for antiplatelet therapy,” Bioorganic & Medicinal Chemistry, vol. 23, no. 12, pp. 2786–2797, 2015.

[41] E. Reimer, M. Stempel, B. Chan, H. Bley, and M. M. Brinkmann, “Protein tyrosine phosphatase 1B is involved in efficient type I interferon secretion upon viral infection,” Journal of Cell Science, vol. 134, no. 5, 2020.

[42] V. J. Bykov, S. E. Eriksson, J. Bianchi, and K. G. Wiman, “Targeting mutant p53 for efficient cancer therapy,” Nature Reviews. Cancer, vol. 18, no. 2, pp. 89–102, 2018.

[43] Y. Wei, Z. Sun, Y. Wang et al., “Methylation in the TP53 promoter is associated with ischemic stroke,” Molecular Medicine Reports, vol. 20, no. 2, pp. 1404–1410, 2019.

[44] M. Li, M. Sun, L. Cao et al., “A TIGAR-regulated metabolic pathway is critical for protection of brain ischemia,” The Journal of Neuroscience, vol. 34, no. 22, pp. 7458–7471, 2014.

[45] J. C. Gomez-Sanchez, M. Delgado-Esteban, I. Rodriguez-Hernandez et al., “The human Tp53 Arg72Pro polymorphism explains different functional prognosis in stroke,” The Journal of Experimental Medicine, vol. 208, no. 3, pp. 429–437, 2011.

[46] F. S. Eshaghi, H. Ghazizadeh, S. Kazami-Nooreini et al., “Association of a genetic variant in AKT1 gene with features of the metabolic syndrome,” Genes & diseases, vol. 6, no. 3, pp. 290–295, 2019.

[47] Y. G. Chen, B. Yin, and B. Y. Luo, “Research progress of Akt signaling pathway and cell survival,” Journal of International Neurology and Neurosurgery, vol. 39, no. 4, pp. 362–365, 2012.
H. R. Luo, H. Hattori, M. A. Hossain et al., “Akt as a mediator of cell death,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 20, pp. 11712–11717, 2011.

W. Zhang, Y. Wu, H. Chen, D. Yu, J. Zhao, and J. Chen, “Neuroprotective effects of SOX5 against ischemic stroke by regulating VEGF/PI3K/AKT pathway,” Gene, vol. 767, 2020.

S. C. Du, Q. Q. Cheng, and C. H. Mu, “Ligustilide in vitro promotes the proliferation of vascular endothelial cells in a simulated ischemic environment,” Sichuan Medical Journal, vol. 41, no. 5, pp. 463–467, 2020.

W. J. Wang, S. Shu, Y. J. Xu, and T. Q. Wang, “Protective effect of gypenoside XVII on cerebral ischemia reperfusion rats by regulating PI3K/Akt signaling pathway,” Chinese Archives of Traditional Chinese Medicine, pp. 1–12, 2020.

M. A. Hannan, R. Dash, A. A. Sohag, M. Haque, and I. S. Moon, “Neuroprotection against oxidative stress: phytochemicals targeting TrkB signaling and the Nrf2-ARE antioxidant system,” Frontiers in Molecular Neuroscience, vol. 13, p. 116, 2020.

W. Zhang, X. Wang, M. Yu, J. A. Li, and H. Meng, “The c-Jun N-terminal kinase signaling pathway in epilepsy: activation, regulation, and therapeutics,” Journal of Receptor and Signal Transduction Research, vol. 38, no. 5-6, pp. 492–498, 2018.

Q. Liu, J. P. Kou, and B. Y. Yu, “Ginsenoside Rg1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-κB activation,” Neurochemistry International, vol. 58, no. 1, pp. 119–125, 2011.

M. Slevin, J. Krupinski, A. Slowik, F. Rubio, A. Szczudlik, and J. Gafigney, “Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke,” Neuroreport, vol. 11, no. 12, pp. 2759–2764, 2000.

C. Bonnans, J. Chou, and Z. Werb, “Remodelling the extracellular matrix in development and disease,” Nature Reviews. Molecular Cell Biology, vol. 15, no. 12, pp. 786–801, 2014.

H. Hohjoh, I. Horikawa, K. Nakagawa, E. Segi-Nishida, and H. Hasegawa, “Induced mRNA expression of matrix metalloproteinases Mmp-3, Mmp-12, and Mmp-13 in the infarct cerebral cortex of photothrombosis model mice,” Neuroscience Letters, vol. 739, p. 135406, 2020.

[50] W. P. Guo, X. G. Fu, S. M. Jiang, and J. Z. Wu, “Neuregulin-1 regulates the expression of Akt, Bcl-2, and Bad signaling after focal cerebral ischemia in rats. This paper is one of a selection of papers published in this special issue entitled “Second International Symposium on Recent Advances in Basic, Clinical, and Social Medicine” and has undergone the Journal’s usual peer review process,” Biochemistry and Cell Biology, vol. 88, no. 4, pp. 649–654, 2010.

N. Noshita, A. Lewén, T. Sugawara, and P. H. Chan, “Evidence of phosphorylation of Akt and neuronal survival after transient focal cerebral ischemia in mice,” Journal of Cerebral Blood Flow and Metabolism, vol. 21, no. 12, pp. 1442–1450, 2001.